Lobbying on 340B issues reached a record level in 2023, according to annual tallies of congressional lobbying disclosures. That flurry [...] …
Category: Pharma Industry
A federal district judge last week denied two community health centers’ antitrust claims against four major diabetes drug manufacturers over [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eight Mississippi state senators have introduced a bill to bar drugmakers from restricting 340B contract pharmacy use and pharmacy benefit [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker GlaxoSmithKline has posted another refund notice to 340B providers related to purchases of its high-earning asthma drugs. A Jan. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
After more than six months of long meetings with stakeholders, a bipartisan group of six senators released draft legislation Friday [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A recent federal district court ruling on the 340B patient definition created a “gray area” for 340B providers and drugmakers, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Congress is unlikely to act on 340B in 2024, but a potential flip of the U.S. Senate could lead to [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
As many attendees gathered for lunch outside at the 340B Coalition Winter Conference in San Diego on Tuesday, the AIDS [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Critics of hospital participation in the 340B discount drug program are ramping up efforts, as a bipartisan group of senators [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The ruling in a recent, high-profile 340B patient definition case will likely result in providers increasing the number of patients [...] …